India, Oct. 26 -- Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company developing small molecule therapeutics, announced the final data from its Phase 2a clinical study of namodenoson in advanced pancreatic ductal adenocarcinoma. The company presented the data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain.
According to the company, the study achieved its primary safety endpoint, demonstrating that oral namodenoson was well tolerated in patients with advanced pancreatic cancer who had received prior systemic therapies.
Namodenoson is an orally administered, selective A3 adenosine receptor agonist that targets a receptor highly expressed in tumour and inflammatory cells.
The single-cen...